Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.60
>-$0.01(-0.33%)
At close: 4:00 PM EDT
$0.60
>-$0.01(-0.33%)
Day’s Range― - ―
52-Week Range$0.51 - $1.83
Previous CloseN/A
Volume5.81K
Average Volume (3M)124.73K
Market Cap
$22.79M
Enterprise Value-$32.86
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageConsistently low debt levels provide durable financial flexibility for a clinical-stage biotech. With modest leverage, the company can prioritize R&D financing, negotiate partnerships, or raise equity without immediate debt-servicing pressure, reducing near-term solvency risk.
Strong Shareholder Backing For TransactionOverwhelming shareholder approval creates procedural certainty for a structural corporate transaction. This backing can unlock strategic restructuring, potential capital or partner commitments, and reduce governance friction—supporting longer-term strategic options.
Management / Governance ActionsAppointment of senior finance leadership and re-elected directors strengthens financial oversight and execution capacity. Improved governance and a dedicated CFO can enhance budgeting, cash management and investor communication over the coming quarters.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow indicate the business consumes cash to sustain operations and trials. This structural cash burn requires repeated external funding, increasing dilution risk and potentially limiting ability to advance programs without partner deals.
Volatile / No Recurring RevenueRevenue volatility and recent absence of revenue signal no stable commercial base; the firm relies on irregular receipts or milestone payments. This undermines predictable funding and makes long-term planning, R&D sequencing, and partner negotiations more challenging.
Listing Compliance / Delisting RiskOngoing minimum-bid noncompliance and transfer to the Capital Market create sustained listing risk. A delisting event would materially reduce liquidity, impair access to public capital and complicate investor relations, constraining financing and strategic options longer term.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $1.83 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $22.79M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Apr 30, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Overvalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 8.514%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
3.04% Other Institutional Investors
96.93% Public Companies and
Individual Investors